تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
11.21 US$
+0.20 US$ · +1.82%
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
الإغلاق السابق
11.21 US$
+0.20 US$ · +1.82%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
نطاق اليوم
السعر الحالي 11.21 US$
نطاق 52 أسبوعًا
السعر الحالي 11.21 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
54
قيمة عادلة
المشاعر
41
مختلط
المخاطر
53
مخاطر أعلى من المعتاد
الزخم
60
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
نطاق اليوم
السعر الحالي 11.21 US$
نطاق 52 أسبوعًا
السعر الحالي 11.21 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (AUD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 1.21 مليار AUD | 783.21 مليون AUD | 502.55 مليون AUD | 160.1 مليون AUD | 7.6 مليون AUD |
| تكلفة البضاعة المباعة | 565.2 مليون AUD | 273.53 مليون AUD | 188.16 مليون AUD | 65.17 مليون AUD | 38.68 مليون AUD |
| الربح الإجمالي | 640.23 مليون AUD | 509.68 مليون AUD | 314.39 مليون AUD | 94.93 مليون AUD | 5.05 مليون AUD |
| البحث والتطوير | 256.82 مليون AUD | 121.03 مليون AUD | 128.84 مليون AUD | 57.86 مليون AUD | 34.14 مليون AUD |
| مصاريف البيع والمصاريف العمومية والإدارية | 356.77 مليون AUD | 207.13 مليون AUD | 134.16 مليون AUD | 87.1 مليون AUD | 46.99 مليون AUD |
| نفقات التشغيل | 613.59 مليون AUD | 427.55 مليون AUD | 263.27 مليون AUD | 186.86 مليون AUD | 53.3 مليون AUD |
| دخل الفوائد | 8.74 مليون AUD | 10.86 مليون AUD | 671 ألف AUD | 1 ألف AUD | — |
| مصاريف الفوائد | 55.06 مليون AUD | 21.46 مليون AUD | 8.94 مليون AUD | 406 ألف AUD | 195.68 ألف AUD |
| الاستهلاك والإطفاء | 32.67 مليون AUD | 8.03 مليون AUD | 6.74 مليون AUD | 5.38 مليون AUD | 5.17 مليون AUD |
| الدخل التشغيلي | 26.64 مليون AUD | 82.13 مليون AUD | 15.84 مليون AUD | −91.93 مليون AUD | −81.25 مليون AUD |
| صافي الدخل | −10.69 مليون AUD | 49.92 مليون AUD | 5.21 مليون AUD | −104.08 مليون AUD | −80.51 مليون AUD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Schwab International Equity ETFSCHF18.45 مليون0.03%67.41 مليار USD0.03%27.27 US$+0.66%
State Street SPDR Portfolio Developed World ex-US ETFSPDW10.33 مليون0.03%40.46 مليار USD0.03%49.98 US$+0.64%
Schwab Fundamental International Small Company Index ETFFNDC5.17 مليون0.17%3.07 مليار USD0.39%49.73 US$+0.73%
John Hancock Investments - Multifactor Developed International ETFJHMD940.45 ألف0.10%964.94 مليون USD0.39%44.09 US$+0.52%
State Street SPDR Portfolio Europe ETFSPEU351.89 ألف0.05%683.39 مليون USD0.07%53.13 US$+0.68%
State Street SPDR MSCI EAFE StrategicFactors ETFQEFA249.01 ألف0.03%995.58 مليون USD0.30%97.685 US$+0.59%
State Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAX212.86 ألف0.04%484.83 مليون USD0.20%53.35 US$+0.73%
ActivePassive International Equity ETFAPIE131.4 ألف0.01%1.14 مليار USD0.45%38.56 US$+0.65%Schwab International Equity ETFSCHFState Street SPDR Portfolio Developed World ex-US ETFSPDWSchwab Fundamental International Small Company Index ETFFNDCJohn Hancock Investments - Multifactor Developed International ETFJHMDState Street SPDR Portfolio Europe ETFSPEUState Street SPDR MSCI EAFE StrategicFactors ETFQEFAState Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAXActivePassive International Equity ETFAPIEالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
